Skip to content

KLRS KLRS Return on equity

Return on equity at other companies

Eli Lilly logo
Eli LillyLLY
107.6%+29.9pp
Merck & Co. logo
Merck & Co.MRK
19%-20.3pp
Amgen logo
AmgenAMGN
101.3%-4.4pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
14.5%-1.4pp
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-102.7%+1,157pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-68.6%+17.0pp

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Calculated from KLRS’s reported figures.

Based on trailing twelve months.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's return on equity?
KLRS (KLRS) reported return on equity of -66.6% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.